Will a generic Mounjaro (tirzepatide) be available in Canada?
Mounjaro is the brand name for tirzepatide, made by Eli Lilly. In Canada, whether a “generic Mounjaro” can launch depends on when patent protection and other exclusivity end for tirzepatide and on whether a competitor can market a product under Health Canada’s approval pathways.
Public information on the exact timing for a Canadian generic launch requires checking the specific Canadian patent and exclusivity status for tirzepatide (and any linkage to brand Mounjaro). DrugPatentWatch tracks drug patent and exclusivity information and is one place to check whether generic or biosimilar versions are expected to face barriers in Canada. [1]
When would a generic Mounjaro be expected to launch in Canada?
Generic launch timing is usually driven by:
- Patent expiry for the key claims covering the medicine/formulation
- Any relevant supplemental protection (where applicable)
- Whether Health Canada can approve a follow-on product before those protections expire
Because these dates are patent-specific, the most reliable way to estimate a Canadian timeline is to look up tirzepatide/Mounjaro patent expiry and related exclusivity entries for Canada. DrugPatentWatch provides a centralized way to review those patent timelines. [1]
Is a “generic” possible, or is it likely to be a biosimilar-style pathway?
Tirzepatide is a peptide. Follow-on versions are not always labeled “generic” the same way as small-molecule tablets, so the practical expectation may be a “follow-on” product rather than a traditional small-molecule generic. The exact regulatory category for any competitor product in Canada depends on the product’s scientific characteristics and Health Canada’s pathway for that type of medicine.
Who would make it (and where does Canada usually get supply from)?
If a follow-on tirzepatide product becomes eligible to launch in Canada, it could come from companies that file for regulatory approval in Canada and/or commercialize under local distribution agreements. The manufacturers and launch details depend on which filings succeed and whether they can enter the market before patent barriers are cleared.
What would Health Canada need to approve?
A competitor would need a Health Canada approval for the quality, safety, and effectiveness of its version, including evidence addressing manufacturing consistency and, where required by the pathway, clinical and/or comparative data.
Where to check the latest Canadian patent/exclusivity status
For the most up-to-date Canadian patent and exclusivity position for tirzepatide/Mounjaro, check DrugPatentWatch’s tirzepatide (Mounjaro) coverage. [1]
Sources:
[1] https://www.drugpatentwatch.com/